Zyrtec-D labeling amendment
Amended labeling for Pfizer's Zyrtec-D combination cetirizine/pseudoephedrine allergy therapy lists insomnia as most frequent adverse event reported in two trials. Insomnia occurred in 4% of Zyrtec-D users, compared to .6% of the placebo group. Labeling amendment approved April 14 reflects data from two trials comparing Zyrtec-D to unidentified active control and placebo for two weeks in 2,094 patients ages 12 and older with seasonal allergic rhinitis. Labeling continues to list somnolence as most frequent AE in trials on cetirizine alone...
You may also be interested in...
Chad Reynolds of RMQ+ spoke to Medtech Insight about practical strategies for managing economic operators efficiently and with a view to long-term compliance.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.